Many oncogenes, including chimeric oncoproteins, require insulin-like growth factor 1 receptor (IGF1R) for promoting cell transformation. The ETS variant 6 (ETV6)-neurotrophic receptor tyrosine kinase 3 (NTRK3) (EN) chimeric tyrosine kinase is expressed in mesenchymal, epithelial, and hematopoietic cancers and requires the IGF1R axis for transformation. However, current models of IGF1R-mediated EN activation are lacking mechanistic detail. We demonstrate here that IGF-mediated IGF1R stimulation enhances EN tyrosine phosphorylation and that blocking IGF1R activity or decreasing protein levels of the adaptor protein insulin receptor substrate 1/2 (IRS1/2) results in rapid EN degradation. This was observed both in vitro and in vivo in fibroblast and breast epithelial cell line models and in MO91, an EN-expressing human leukemia cell line. Stable isotope labeling with amino acids in cell culture (SILAC)-based MS analysis identified the E3 ligase RING-finger protein 123 (Rnf123, more commonly known as KPC1) as an EN interactor upon IGF1R/insulin receptor (INSR) inhibitor treatment. KPC1/Rnf123 ubiquitylated EN in vitro, and its overexpression decreased EN protein levels. In contrast, KPC1/Rnf123 knockdown rendered EN resistant to IGF1R inhibitor-mediated degradation. These results support a critical function for IGF1R in protecting EN from KPC1/Rnf123-mediated proteasomal degradation. Attempts to therapeutically target oncogenic chimeric tyrosine kinases have traditionally focused on blocking kinase activity to restrict downstream activation of essential signaling pathways. In this study, we demonstrate that IGF1R inhibition results in rapid ubiquitylation and degradation of the EN onco-protein through a proteasome-dependent mechanism that is reversible, highlighting a potential strategy for targeting chimeric tyrosine kinases in cancer.
A number of well known dominantly acting oncogenes, including activated Ras and chimeric oncoproteins, require the presence of the insulin-like growth factor 1 receptor (IGF1R) 3 for transformation (1) (2) (3) (4) . Despite this, the actual mechanistic role of IGF1R in transformation remains unclear. To further understand IGF1R's role in transformation, we utilized cells expressing ETV6 -NTRK3 (EN), a dominantly acting chimeric tyrosine kinase (TK) expressed in pediatric sarcomas (5, 6) , acute leukemia's (7) , secretory breast carcinoma (8) , mammary analog secretory carcinoma salivary gland tumors (9) , radiation induced thyroid carcinomas (10) , diffuse intrinsic pontine glioma and low-grade glioma (11) , and most recently in colorectal carcinomas (12) and inflammatory myofibroblastic tumors (13) . EN is generated by the t(12;15)(p13;q25) chromosomal translocation, fusing the sterile ␣-motif dimerization domain of the ETV6 transcription factor to the protein-tyrosine kinase domain of the neurotrophin-3 receptor (NTRK3) leading to constitutive activation of the NTRK3 protein-tyrosine kinase domain (8, 14, 15) . Emphasizing the importance of this work, there is currently great interest in targeting NTRK fusions in human tumors (16) .
Our previous work showed that EN expression in NIH3T3 fibroblasts constitutively activates two major effector pathways of wt NTRK3, namely the Ras-Erk and phosphatidylinositol 3-kinase (PI3K)-AKT cascades, and that EN transformation is attenuated through inhibition of either pathway (17) . More-over, EN requires an intact IGF1R signaling axis to transform cells, and IGF1R kinase inhibitors block EN tumorigenesis in vivo (3, 18) . Although IGF1R activity is not essential for EN to activate Ras-ERK, EN stimulation of the PI3K pathway requires IGF1R (19) . We then found that EN membrane localization is necessary for activation of PI3K-AKT but not Ras-ERK. Membrane localization of EN is facilitated by its constitutive binding to insulin receptor substrate 1 and 2 (IRS1/2), members of the IRS adaptor protein family (20) . EN-IRS1/2 complexes then translocate to the plasma membrane to bind to activate IGF1R via IRS1/2 (21) . Therefore the current model is that activated IGF1R acts to tether EN-IRS1/2 complexes to the plasma membrane to fully activate EN transformation pathways.
Based on the above mechanism, we further hypothesized that IGF1R might directly Tyr phosphorylate and activate EN at the plasma membrane. We therefore tested the effects of stimulating EN-transformed cells with the IGF1R ligand, IGF1. We now report that IGF1 indeed increases overall Tyr phosphorylation of EN. Surprisingly, however, the mechanism is not through direct IGF1R-mediated EN phosphorylation but rather through increased EN stability via rescue of EN from proteasome-mediated degradation. Furthermore, we identify KPC1, a RING domain-containing E3, as a specific EN interactor when IGF1R activity is blocked. KPC1 ubiquitylates EN under these conditions, and ubiquitylated EN is promptly degraded by the proteasome. Together, our data support a model whereby IGF1R activation stabilizes the EN fusion protein by protecting it from KPC1-mediated proteasomal degradation.
Results

Inhibition of IGF1R activity decreases total EN protein levels
We previously demonstrated that EN transforms murine fibroblasts (NIH3T3 and mouse embryo fibroblasts) (14) , murine-derived EpH4 breast epithelial cells (8) , and human MCF10A breast epithelial cells (15) and that the oncogenic potential of EN critically depends on IGF1R activity (3) . ENoverexpressing NIH3T3, EpH4, and MCF10A cell lines show IGF1R expression and EN activation of AKT and ERK1/2, which promote an increased proliferative response through enhanced cyclin D1 expression ( Fig. 1a ). One exception is the lack of increased phospho-AKT in EN EpH4 cells, because increased phospho-AKT levels are most clearly observed in EN EpH4 cells when they are grown in three dimensional Matrigel cultures, as previously described (18) . Because IGF1R localizes EN to the plasma membrane to activate the PI3K-AKT pathway (19, 21) , we wondered whether IGF1R might also directly phosphorylate and activate EN. To test this, we assessed EN Tyr phosphorylation in EN-transformed EpH4 breast cells (EN EpH4) after IGF1 stimulation, which strongly increased Tyr phosphorylated levels of both EN and IGF1R in a time dependent manner (Fig. 1b ). Inhibiting IGF1R activity in EN EpH4 cells with BMS-536924, a small molecule TK inhibitor of IGF1R and the insulin receptor (INSR) (22) , almost completely blocked EN (and IGF1R) Tyr phosphorylation in response to IGF1 (Fig. 1c ). To extend this to other cell lines, we tested ENtransformed MCF10A breast cells (18) and NIH3T3 fibroblasts (17) . Unexpectedly, treatment with BMS-536924 or another IGF1R inhibitor, PPP (23) , not only reduced EN Tyr phosphorylation (not shown) but also reduced total EN expression levels in EN MCF10A cells ( Fig. 1d ) and BMS-536924 -treated EN NIH3T3 cells ( Fig. 1e , upper panels). BMS-536924 had no effect on ectopic expression levels of WT NTRK3 protein levels ( Fig.  1e , lower panels), arguing against a general effect on translation. BMS-536924 did not alter EN mRNA transcript levels in EN NIH3T3 cells ( Fig. 1f ), arguing against a transcriptional effect on EN expression. Similarly, although less effectively, use of IGF1-blocking antibodies (␣-IR3 and CP-751-871) (24, 25) on EN EpH4 or EN MCF10A cells Fig. 1 (g and h, respectively) or siRNAs targeting IGF1R of EN NIH3T3 cells ( Fig. 1i ) also decreased EN total protein levels, although only at the highest concentrations used.
We previously demonstrated that EN forms a tripartite complex with IGF1R and IRS1/2 to mediate a physical association between EN and IGF1R and that this complex is critical for EN-mediated transformation (21) . We therefore administered siRNAs specifically targeting IRS1 ( Fig. 2a ) or IRS2 ( Fig. 2b ) to EN NIH3T3 cells and observed that IRS1 knockdown was less effective than IRS2 knockdown in reducing EN levels, potentially indicating differential utilization of IRS1 versus IRS2 in these cells. This suggests that, at least in EN NIH3T3 cells, IRS2 also contributes to EN protein stability, in this case through enhancing EN-IRS2-IGF1R complex formation. Moreover, the pan-NTRK kinase inhibitor K252a also led to a dose-dependent decrease in total EN levels in EN NIH3T3 cells ( Fig. 2c ), consistent with our previous observation that only kinase active EN participates in EN-IRS2-IGF1R complexes. Together, these results indicate that blocking formation of the EN-IRS-IGF1R complex reduces total EN protein levels. In support of this notion, treatment of MO91, a human leukemia cell line, endogenously expressing EN (26) with BMS-536924 or the PPP IGF1R inhibitor exhibited decreases on phosphorylated and total IGF1R ( Fig. 2d ) and EN protein levels ( Fig. 2e ). Moreover, these cells underwent marked apoptosis in response to IGF1R inhibition ( Fig. 2f ). Thus, the effects of IGF1R inhibition on EN protein levels are not limited to model systems of exogenously expressed EN.
We next tested whether the effects of IGF1R inhibition on EN levels are reversible, using EN NIH3T3 cells. Indeed, both the levels of EN and known readouts of EN activation (phospho-AKT and MEK, cyclin D1, and EN Tyr phosphorylation; Fig. 3a ), as well as loss of morphological transformation (Fig.  3b ), were rescued 24 h after BMS-536924 withdrawal. To confirm these observations in vivo, the orally available IGF1R inhibitor BMS-754807 (27) was administered by oral gavage to EN EpH4 tumor-bearing mice as previously described (18) , with K-Ras-expressing tumors as negative controls. BMS-754807 dramatically reduced EN protein levels ( Fig. 3c , left panel) and blocked EN-induced tumor cell proliferation as assessed by BrdU staining of tumor sections ( Fig. 3d ). In support of these results, BMS-536924 treatment only decreased cyclin D1 levels in EN EpH4 cells, but not in K-Ras EpH4 cells ( Fig. 3e ). This notion is further supported in a previous publication whereby BMS-536924 treatment blocks EN EpH4 tumor formation (18) . Moreover, BMS-536924 treatment of EN or Blocking IGF1R activity results in EN protein degradation K-Ras NIH3T3 cells had an effect on the transformed morphology of EN NIH3T3 cells ( Fig. 3f ). Taken together, these results strongly indicate that BMS-536924 shows no off-target effect on K-Ras downstream activation but is specific to IGF1R inhibition that reduces EN protein levels both in vitro and in vivo. The cells were serum-starved for 24 h prior to harvesting. HSC70 and actin were used as loading controls. b, immunoblotting for phosphotyrosine using EN-IP lysates from IGF-1-stimulated EN-expressing murine breast epithelial cells (EpH4) shows increased EN Tyr phosphorylation over time. c, immunoblotting for IGF1RB and EN using phosphotyrosine-IP lysates from EpH4 cells treated with BMS-526924 for 4 h blocks IGF-1-induced EN Tyr phosphorylation. d, increasing concentrations of IGF1R kinase inhibitors BMS-536924 or PPP decreases total EN protein levels in the human breast epithelial EN MCF10A cell line. e, BMS-536924 treatment for 4 h decreased total EN levels in a dose-dependent manner and has no effect on NIH3T3 cells ectopically expressing full-length wt NTRK3 receptor. Actin was used as a loading control. f, upper panel, BMS-536924 treatment of EN NIH3T3 cells for 1 and 4 h shows no effect on EN mRNA expression when compared with DMSO vehicle-treated cells. Lower panel, immunoblotting for EN using whole-cell lysates from the same EN NIH3T3 BMS-536924 -treated cells shows an effect on EN protein expression. g, the murine-specific IGF1R-blocking antibody ␣-IR3 decreases both EN Tyr phosphorylation and total EN protein levels in the murine breast epithelial cell line EpH4 in a dose-dependent manner. h, the human-specific IGF1R-blocking antibody CP-751-871 produces a dose-dependent decrease in EN Tyr phosphorylation in the human breast epithelial EN MCF10A cell line. i, total EN protein levels are decreased upon using increasing concentrations of a siRNA pool targeting IGF1RB in EN NIH3T3 cells. P, phospho; Tot, total; IB, immunoblot; ST, serum treatment; pre-tx, pretreatment; 4G10, anti-phosphotyrosine antibody.
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We next wished to determine the mechanism by which IGF1R inhibition reduces EN protein levels. As mentioned, IGF1R inhibition did not affect EN transcript levels ( Fig. 1f) , pointing instead to effects on protein stability or mRNA trans-lation. Next, we assessed the kinetics of BMS-536924-mediated loss of EN protein expression. This revealed EN degradation to be a rapid process starting within minutes in both EN-overexpressing NIH3T3 cells ( Fig. 4a ) and within an hour in endogenous EN-expressing MO91 cell lines ( Fig. 4b ). We then directly Figure 2 . siRNAs targeting IRS2 decrease EN total protein levels. a and b, increasing concentrations of siRNA pools targeting IRS2 decreases total EN protein levels in EN NIH3T3 cells (but not IRS1). Densitometric quantification of IRS1/2 and EN expression normalized to actin loading controls is shown graphically next to blots. c, effects on EN protein levels from increasing doses of BMS-536924 or the pan-NTRK inhibitor K252a. Actin was used as a loading control. d and e, effects of increasing concentrations of BMS-536924 and PPP on the endogenously EN-expressing MO91 human leukemia cell line, showing tyrosine-phosphorylated and total IGF1R protein expression in d and EN protein levels in e. EN protein is expressed as a single band at ϳ50 kDa in MO91 cells (26, 48) . GAPDH and HSC70 were used as loading controls. f, effects of IGF1RB inhibitors on MO91 cell survival after 24 h of incubation with increasing concentrations of inhibitor. The percentage of cell death is calculated from FACS analysis performed on annexin V-and propidium iodide-stained cells. The results are shown as scatter plots with individual data points and S.D. from triplicate wells to represent experimental variation. The Western blotting panels used to create figures in a-e have been cropped. BMS, BMS-536924; conc., concentration; C, control siRNA. tested whether BMS-536924 alters EN protein stability. We used cycloheximide (CHX) to block new protein synthesis and treated NIH3T3 cells transformed by hemagglutinin (HA)tagged EN with BMS-536924 in the presence or absence of the MG132 proteasome inhibitor (Fig. 4c ). EN expression in untreated cells (i.e. CHX only treatment) is relatively stable over an 8-h time period (lanes 2-4) . BMS-536924 treatment for 2 h reduced EN expression to almost undetectable levels (lanes 5-7), and this effect was significantly blocked by addition of the MG132 proteasome inhibitor (lanes 8 -10) but was unaffected by treatment with the lysosome inhibitor chloroquine (lanes [11] [12] [13] . This suggests that BMS-536924 reduces EN protein stability, which can be blocked by MG132. To determine whether EN is ubiquitylated in response to BMS-536924, we 
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used a GFP-trap system to isolate GFP-tagged EN expressed in HEK293 cells ( Fig. 4d ) and probed for polyubiquitin ( Fig. 4e ). BMS-536924 treatment again led to loss of GFP-EN, but this was completely rescued by MG132 co-treatment under these conditions, providing strong evidence that EN is degraded by the proteasome in the presence of BMS-536924 (Fig. 4d , lane 3, top blot, GFP (Lighter)). Simultaneous treatment with BMS-536924 and MG132 produced prominent smears of polyubiquitylated EN species after GFP pulldowns (Fig. 4e, lane 4) , further supporting that EN is polyubiquitylated and degraded by the proteasome after BMS-536924 treatment. Specificity of the GFP-trap assay was demonstrated because no stained proteins were detected upon scanning the region at the expected EN protein size above the GFP band in the GFP alone lane of the Ponceau-stained membranes (Fig. 4d, lane 1, lower panels) . Likewise, no high-molecular-weight polyubiquitin smears were detected in the GFP alone sample (Fig. 4e, lane 1) , demonstrating specificity of the GFP-trap assay for EN polyubiquitylation.
EN interacts with the KPC1/Rnf123 E3 ligase in BMS-536924treated cells
We next wished to elucidate the mechanism responsible for increased EN polyubiquitylation and degradation upon IGF1R inhibition. One possibility is that blocking IGF1R alters binding of EN to an E3 ligase enzyme otherwise targeting EN for proteasomal degradation. To test this we performed stable in vitro labeling by amino acids in cell culture (SILAC)-based MS analysis, as described under "Experimental Procedures" and depicted schematically in Fig. 5 to identify proteins that preferentially interact with EN under BMS-536924 treatment. This identified a number of proteins that were preferentially enriched as potential EN interactors in cells treated with BMS-536924, based on two or more peptides and greater than 2-fold enrichment in cells expressing EN and treated with BMS-536924, compared with cells expressing EN but treated with DMSO (Table S1 ). Among these, we identified two known E3 ligases, ZNFR1 and KPC1/Rnf123, as being highly enriched in BMS-536924-treated cells. However, of these, manual validation of the MS spectra and peak ratios for ZNFR2 were of low quality, but not for KPC1 (data not shown). We therefore focused on KPC1 as a potential interactor and E3 ligase for EN. This protein, along with its co-factor, KPC2, comprises the Kip1 ubiquitylation-promoting (KPC) complex, which is known to regulate the ubiquitin-dependent degradation of the cyclin-dependent kinase inhibitor p27 at the G 1 phase of the cell cycle (28) .
The KPC1/2 complex polyubiquitylates EN in vitro to mediate its degradation
To test whether KPC1 modulates EN stability, we first validated that KPC1 interacts with EN in co-IP experiments, using HEK293 cells expressing HA-tagged EN and Flag-tagged KPC1 (Fig. 6a ). Using the same system, we then demonstrated an increased interaction between HA-EN and Flag-KPC1 under BMS-536924 treatment. Without BMS-536924 inhibitor EN is protected from KPC1 interaction and ubiquitylation by active IGF1R signaling (Fig. 6b ). We propose that without addition of the BMS-536924 IGF1R inhibitor, EN is protected from the KPC1 interaction and subsequent ubiquitylation through active IGF1R signaling (Fig. 6b , third lane, HA IP: FLAG IB). BMS-536924 treatment also induced an increased interaction between endogenous KPC1 and EN in MCF10A cells (Fig. 6c,  top blot) . This was most evident at the 15-min time point, likely because by the 60-min time point, EN degradation would already be appreciable and therefore rate-limiting in this experimental setting.
We next tested whether the KPC complex can ubiquitylate EN. We therefore performed in vitro ubiquitylation assays using purified proteins produced in Sf21 insect cells. His 6 -Flag-KPC1 and His 6 -HSV-KPC2 proteins were generated and verified using Coomassie-stained PAGE gels (Fig. 6d ). His 6 -4HA-EN protein was purified by Ni 2ϩ -agarose chromatography and mixed with the KPC complex in the presence of GSTubiquitin. Notably, accumulation of high-molecular-weight EN species increased with time, which was observed as early as 30 min and increased up to 2 h after mixing (Fig. 6e ). We next verified that ubiquitylation of EN by the KPC1/2 complex required the combined presence of the E1 (Uba1), E2 (UbcH5a (28)), and E3 enzymes with ubiquitin ( Fig. 6f ). We then 
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extended this assay to test a panel of other purified E2 enzymes (Fig. 6g ). In addition to UbcH5a, Ubc4 also mediated KPC1/2 ubiquitylation of EN (Fig. 6h ).
To confirm these results, we performed KPC1 knockdown using two independent siRNAs (KPC1#5 and #12) in EN NIH3T3 cells, which stabilized EN protein expression even in the presence of BMS-536924 ( Fig. 7a) . Moreover, ectopic expression of wt KPC1, but not KPC2 alone nor a nonfunctional RING domain-deleted form of KPC1 (KPC1⌬RING; as depicted in Fig. 7b ), blocked EN-mediated morphological transformation of NIH3T3 cells (Fig. 7c) . Consistent with this, soft agar colony formation was significantly inhibited in two independently derived EN-transformed NIH3T3 cell lines engineered to ectopically express wt KPC1 (designated A and B), compared with control EN-transformed cells (Fig. 7d ). WT KPC1 overexpression in both A and B cell lines decreased total levels of EN even in the absence of BMS-536924, which was not observed in cells overexpressing KPC2 or KPC1⌬RING (Fig.  7e ). Finally, we tested whether the KPC1/2 complex alters EN stability.
Ectopic expression of Flag-tagged KPC1 appears to reduce the half-life of EN after CHX was administered to EN-transformed NIH3T3 cells to block new protein synthesis (Fig. 7, f  and g) . Taken together, these results support a role for KPC1 in concert with its E2 enzymes Ubc4 or UbcH5A in mediating polyubiquitylation and degradation of EN, a process that is enhanced by an as-yet unknown mechanism when the IGF1R axis is inhibited.
Discussion
Clinical targeting of dominantly acting chimeric TKs such as BCR-ABL has been successful because of the development of selective small molecule inhibitors that occlude or alter the ATP-binding pocket within the kinase domain (29) . This well established mechanism of action blocks the aberrant constitutive downstream signaling pathways initiated by chimeric TK domains that are ultimately responsible for increasing cell cycle progression and inhibiting apoptosis in cancer cells. Our previous studies of EN support this paradigm (14, 17) but indicate that another TK, IGF1R, also contributes to EN activation (3, 18 -20) . Through IRS adaptor proteins, IGF1R tethers EN to the plasma membrane (21) , where EN can activate downstream signaling pathways essential for transformation (19) . We now find that inhibition of IGF1R or EN kinase activities or disrupting the EN-IRS-IGF1R complex by depleting IRS proteins, leads to increased EN ubiquitylation and a rapid decrease in EN protein levels. These in turn blocks the transformed phenotype in EN-expressing cell lines and decreases tumor cell proliferation in vivo. We identify KPC1, an E3 ubiquitin ligase previously reported to target p27 for degradation and thereby regulate the G 1 -G 2 transition of the cell cycle (30) , as an EN interactor and a potential E3 ligase for proteasome-mediated degradation of EN. Because KPC2 overexpression did not influence the degradation of EN (Fig. 7e) , then either KPC2 levels are not limiting for this process or KPC1 uses an as-yet unknown co-factor for EN targeting. We cannot rule out the possibility that KPC1 acts indirectly on additional proteins that could themselves directly influence the stability of EN. Notably, KPC2 was not identified as a co-immunoprecipitating protein with EN under BMS-536924 treatment by SILAC mass spec, possibly because of weak interactions with the EN-KPC1 complex under the conditions tested. Furthermore, in MO91 cells, a human leukemia cell line endogenously expressing EN, we observed that reducing EN protein levels promotes cell death (Fig. 2f) . These results suggest that inducing EN degradation could block tumor growth and potentially trigger apoptosis.
The mechanism by which IGF1R inhibition (or disruption of the EN-IRS-IGF1R complex) increases KPC1-mediated EN degradation remains unknown. One obvious possibility is that IGF1R is required to activate EN, as suggested in Fig. 1b , and that the activated, tyrosine-phosphorylated form of EN is resistant to KPC1 binding, ubiquitylation, and degradation. Consistent with this, targeting of the NTRK3 kinase domain with K252a inhibitor also reduced EN protein expression ( Fig.  2c) . It is intriguing to speculate that IGF1R directly Tyr phosphorylates EN to render the latter resistant to KPC1 binding. Related to this possibility, membrane localization of EN through complex formation with activated IGF1R, as we described (21) , may prevent KPC1 binding and degradation. This would explain why IRS2 knockdown also destabilizes EN in the absence of IGF1R inhibition (Fig. 2b) . Also unknown are the sites for KPC1/2-mediated degradation. A total of 28 lysines are present in EN, 9 in the ETV6 portion and the remainder in the NTRK3 portion of the chimeric protein. We recently identified Lys 99 as an essential residue within the ETV6 -sterile ␣-motif dimerization polymer interface that is required for ENmediated transformation because of its participation in a salt bridge that is required for high molecular mass complex formation (31) . Five additional lysine residues are predicted to be ubiquitylated (UbPred; http://www.ubpred.org/cgi-bin/ubpred/ ubpred.cgi; Ref. 49) including Lys 11 , Lys 303 , Lys 391 , and Lys 456 , which possess medium confidence scores, and Lys 254 , which possesses a high confidence score. Three of these residues, including Lys 254 , are located within the ETV6 portion, raising the possibility that ubiquitin-mediated protein degradation regulates other ETV6-containing fusion proteins. Notably, residue Lys 11 has been previously shown to be SUMOylated (32), targeting ETV6 for eventual proteasomal degradation (33) . Our group previously showed that deletion of the final 20 amino acids within the NTRK3 protein, a region required for IRS binding, abrogates EN-mediated transformation (20) . This C-terminal region also includes Lys 616 and Lys 623 , and Lys 623 is within a consensus ubiquitylation sequence of the tumor necrosis factor receptor 6 -p62 (sequestosome-1-SQSTM1) complex. Whether any of these lysines are involved in regulating EN protein stability remains to be determined.
Other examples of proteasome-mediated degradation of fusion proteins have been reported. The ETV6 -JAK2 fusion protein undergoes degradation mediated by SOCS1, a SOCS box-containing E3 ubiquitin ligase (34) . Paradoxically, SOCS1 is up-regulated in ETV6 -JAK2 transformed cells, and although it interferes with ETV6 -JAK2 catalytic activity by degrading the fusion protein, it also protects ETV6 -JAK2-expressing cells from the anti-proliferative effects of interferon-␥ (35) . Alltrans-retinoic acid and arsenic trioxide induce degradation of the PML-RARA fusion protein, which functions as a transcriptional repressor in acute pro-myelocytic leukemia, which mediates both differentiation arrest and leukemogenesis (36) . Both drugs appear to promote degradation of PML-RARA, but by distinct molecular mechanisms. All-trans-retinoic acid activates catabolic pathways to direct proteasome-dependent degradation, whereas arsenic trioxide initiates SUMOylation of Blocking IGF1R activity results in EN protein degradation PML-RARA, which promotes RNF4-mediated ubiquitylation and proteasomal degradation (37, 38) . These two drugs have been used effectively in combination to induce clinical remission of acute pro-myelocytic leukemia patients (39, 40) . Two other fusion proteins, BCR-ABL and TPMRSS2-ERG, found in chronic myeloid leukemia and prostate cancer, respectively, are degraded when cells are treated with WP1130, a small molecule inhibitor that targets the deubiquitinase, USP9X (41, 42) . These examples, along with the work on EN presented here, highlight the notion that inhibiting processes that stabilize fusion proteins may represent a novel approach to clinically target chimeric oncoproteins found in different types of cancers.
Experimental procedures
Constructs MSCV control plasmid was obtained from Clontech. ETV6 -NTRK3 cDNA was cloned into MSCVpuro as previously described (14) . WT NTRK3 (a generous gift from David Kaplan, Hospital for Sick Children, Toronto, Canada) was cloned into MSCVpuro. GFP-EN was constructed as previously described (43) . A linker (ggtggcggtggctctggaggtggtgggtcc) was added between the GFP moiety and the EN fusion protein to increase fluorescence of the fusion protein. WT and RING domaindeleted KPC1-Flag and WT KCP2-HA constructs were as previously described (28, 30) .
Compounds
The following IGF1R kinase inhibitors and IGF1 blocking antibodies were used: BMS-536924 (22) , PPP (44), BMS-754807 (27, 45) , CP-751-871 (25) , and ␣-IR3 (24) . Both BMS inhibitors were a generous gift from M. Pollak (Lady Davis Research Institute, McGill University, Montreal, Canada). The concentrations used for each inhibitor are indicated in each figure and legend.
Cell culture
NIH3T3 and MCF10A cells were purchase from ATCC and were cultured as described (17, 18) . EpH4 cells were obtained from Martin Oft (Schering-Plough Biopharma) and grown as described (18) . MO91 cells (46) were a generous gift from Mikko Taipale (Whitehead Institute, MIT) and were grown in 10% fetal bovine serum/RPMI medium. All breast epithelial cell lines were tested routinely for their ability to respond to basement membrane by undergoing alveolar morphogenesis and to express differentiated protein products such as the mouse milk protein ␤-casein or epithelial markers such as E-cadherin. The cell lines were engineered via retroviral transduction to stably express the vector control (MSCV puro) or ETV6 -NTRK3 (EN puro or EN neo) alone as described (18) or in combination with WT or RING domain-deleted KPC1-Flag or WT KPC2 or transiently transfected with HA-or GFP-tagged EN constructs,
Inhibitors and siRNAs
The following siRNAs were from Dharmacon: IGF1R catalog no. J-056843; mouse IRS1 catalog no. J-040503; mouse IRS2 catalog no. J-040284; and mouse KPC1/Rnf123 J-065652-5 and J-065652-12. The siRNA concentrations used in each experiment are indicated within the figure legends.
Propidium iodide/annexin V staining and FACS analysis of MO91 cells
MO91 cells were incubated in increasing concentrations of BMS-536924 or PPP for 24 h. The cells were then stained with propidium iodide (Sigma) and annexin V (Clontech) and FACS analyzed to determine the percentage of cell death under each treatment condition (n ϭ 3). The data are graphically shown in Fig. 2f .
Testing the efficacy of BMS-754807 using an in vivo tumor model system
A previously described subcutaneous EN EpH4 tumor model (8) was used to test the effects of IGF1R inhibition on EN protein levels. Prior to sacrifice, tumor-bearing mice were administered 1 or 2 mg/kg of BMS-754807/PEG400/distilled H 2 O (80: 20) or vehicle alone by oral gavage. BrdU was administered via IP injection 1 h before sacrifice. Tumors were fixed in formaldehyde and paraffin-embedded, and sections were stained with anti-BrdU antibodies (1:500; Sigma). Animal in vivo study protocols were approved by the Animal Care Committee at the University of British Columbia, with the protocol number A15-0020 and conducted in compliance with standard operating procedures.
Western blotting
Lysates were prepared, and EN was immunoprecipitated as described previously (19) . The following antibodies were used for Western blotting: NTRK3 (1:500; Santa Cruz); 4G10 (1:10,000; Millipore); GAPDH (1: 2000; Abcam); INSR␤(1: 1000; Santa Cruz); IGF1R␤ (1:1000; Santa Cruz); phospho-IGF1RB/INSRB (Y135/1135 and Y1150/1151; 1:500; Cell Signaling); IRS-1 (1:1000; Santa Cruz); IRS2 (1:1000; Upstate); Flag (1:1000; Sigma); HA (1: 2000; Covance); KPC1 (1:500; Santa Cruz); polyubiquitin (1:1000; BD Bioscience); GFP (1:1000; Cell Signaling); LC3 (1:1000; Novus Biologicals); Actin (1:500; Santa Cruz); Cyclin D1 (Clone 504; 1:2000; Upstate); HSC70 (1:1000; Santa Cruz); phospho-ERK1/2 (T202/Y204; 1:1000; Cell Signaling); phospho-AKT (S473; 1:1000; Cell Signaling); phospho-MEK1/2 (S217/221; 1:1000; Cell Signaling); and total AKT (1:1000; Cell Signaling). The dotted lines in the Western blotting panels indicate where the blots have been cropped and joined. Each experiment shown was performed at least twice.
SILAC MS analysis of EN interactors
Vector control or EN transfected NIH3T3 cells were grown for one month in SILAC medium containing light (Arg0/Lys0), medium (Arg6/Lys4), or heavy (Arg10/Lys8) amino acids.
(Numbers refer to light, medium, and heavy nonradioactive isotopic labeling of the amino acids.) These cell lines were then treated with or without 100 nM BMS-536924 for 1 h as shown in Fig. 5 and lysed as previously described (19) . Equal volumes of all three clarified lysates were mixed together, and an anti-NTRK3 immunoprecipitation was performed as previously described (43) . After the addition of SDS sample buffer, the Blocking IGF1R activity results in EN protein degradation samples were shortly run into 4 -12% precast NuPAGE gels (Invitrogen) prior to in-gel tryptic digestion. The HPLCelectrospray ionization-tandem MS was performed on a lineartrapping quadrupole Orbitrap mass spectrometer (LTQ-Orbitrap; Thermo Fisher Scientific) using standard procedures (47) . The instrument was coupled to an Agilent 1100 Nano-HPLC (Agilent, Santa Clara, CA, USA) using a nano-electrospray ionization interface. The tandem MS spectra emanating from the gel was concatenated and searched against the IPI mouse database using Mascot (Matrix Science, Boston, MA). Proteins identified with at least two unique peptides (at least 8 amino acids long) were retained, and protein quantification was determined by MSQuant and manually validated for candidate BMS-536924 affected proteins. Candidate EN-interacting proteins were those that showed greater than 2-fold change between cells expressing EN with BMS-53692 treatment (medium) compared with vector expressing cells treated with BMS-53692 (light). Candidate EN interacting proteins up-regulated by BMS-536924 were those that showed greater than 2-fold change between cells expressing EN with BMS-53692 treatment (medium) compared with EN-expressing cells vector treated with DMSO (heavy). All protein information is found in Table S1 . NIH3T3 cell lines used for the SILAC mass spectrometric analysis were engineered via retroviral transduction to stably express control (MSCVpuro) and EN (ENpuro) as described (8) .
Monolayer morphology and soft agar colony formation assays
Monolayer morphology of stably expressing NIH3T3 cells (Control and EN alone or EN co-expressing KPC1 or KPC2 or KPC1⌬RING) was captured using a Zeiss Axioplan 2 microscope and Northern Eclipse (version 5.0) software. Contrast was adjusted equally using Adobe Photoshop. Soft agar colony formation was assessed as previously described (43) . The experiment was performed in triplicate.
In vitro ubiquitylation assays
ETV6 -NTRK3 tagged with 4HA at the N terminus was subcloned into the pFastBac HT C vector (Invitrogen). The recombinant baculovirus encoding ETV6 -NTRK3 was generated with the Bac-to-Bac baculovirus expression system (Invitrogen). His 6 -4HA-ETV6 -NTRK3 was purified by Ni 2ϩ -agarose chromatography from lysates of Sf21 cells that had been infected with the baculovirus encoding ETV6 -NTRK3. The complex of His 6 -FLAG-0KPC1 and His 6 -HSV-KPC2, Uba1-His 6 , His 6 -Ubc2A, His 6 -Ubc3, His 6 -Ubc4, His 6 -UbcH5A, His 6 -UbcH6, His 6 -UbcH7, His 6 -UbcH8, and GST-ubiquitin were purified as described previously (28) . To determine the ability of the recombinant KPC complex to support the ubiquitylation of ETV6 -NTRK3, we incubated the KPC complex (200 ng) for 2 h at 26°C with 30 ng of Uba1, 50 ng of UbcH5A, 3 g of GST-ubiquitin, and 30 ng of ETV6 -NTRK3 in a final volume of 10 l, containing 40 mM Tris-HCl (pH 7.5), 60 mM NaCl, 1 mM DTT, 5 mM MgCl 2 , 0.5 mM EDTA, 10% glycerol, and 1.5 mM ATP.
Cycloheximide chase experiments
HA-tagged EN-expressing NIH3T3 cells were treated with 10 M of CHX Ϯ 250 nM BMS-536925, Ϯ 10 M MG132, or Ϯ 25 nM chloroquine. The cells were lysed over an 8-h time period using SDS sample buffer and Western blotted for HA to detect EN. Actin was used as a loading control. A second experiment was performed on EN-transformed cells engineered to co-express WT KPC1 and treated with CHX (10 M). The cells were lysed in SDS sample buffer over a 24-h time course and Western blotted using NTRK3 and Flag antibodies to detect EN and KPC1, respectively. Densitometry was used to quantify the amount of EN present in each cell line over the time course. Actin was used as a loading control and to normalize EN total protein levels.
Polyubiquitylation assays
HEK293 cells were first transfected with GFP-EN. After 24 h the GFP-EN cells were split into three dishes and either left untreated or treated with 100 nM BMS-536924 alone, 10 M MG132 alone, or 100 nM BMS-536924 plus 10 M MG132 for 24 h. The cells were lysed as previously described (19) , and GFP TRAP beads (ChromoTEK) were used to capture the GFPtagged EN. Protein was eluted from the beads using sample buffer and boiling. The cell lysates were split in half and run on two separate gels, Western blotted, and probed for either GFP or polyubiquitin. 
